LIMN
Liminatus Pharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About LIMN
Liminatus Pharma, Inc.
A preclinical biopharmaceutical company developing novel immunomodulatory cancer therapies
6 Centerpointe Drive #625, La Palma, CA 90623
--
Liminatus Pharma, Inc., a Delaware corporation, was founded on November 23, 2022. Liminatus is a preclinical stage biopharmaceutical company developing novel immunomodulatory cancer therapies. The company's candidate IBA 101 is a humanized anti-CD47 monoclonal antibody. Initial indications for next-generation CD47 checkpoint inhibitors are expected for patients with advanced solid cancers, including non-small cell lung cancer. As a leading global biopharmaceutical company, the company's vision is to develop a broad range of transformative therapies for cancer patients.
Company Financials
EPS
LIMN has released its 2022 Q2 earnings. EPS was reported at 0.11, versus the expected 0, beating expectations. The chart below visualizes how LIMN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
